About Qu Biologics

Qu Biologics has discovered how our body’s immune response to acute infection helps our body clear cancer and other chronic inflammatory diseases. To learn more, read How SSIs Work. SSIs, which are derived from components of inactivated bacteria, are designed to activate the body’s innate immune response and restore normal immune function in the targeted organ or tissue to reverse the chronic inflammation underlying many chronic diseases including cancer, inflammatory bowel disease and other immune-related conditions. By restoring and empowering your own immune system, SSIs are designed to treat disease differently.

We bring excitement and passion to our work every day with the goal of creating treatments that will positively impact the lives of people living with chronic disease. Qu Biologics’ founder and CEO, Dr. Hal Gunn, is a clinician who for 20 years has worked to understand the link between our immune system and chronic disease, including cancer. Qu Biologics’ Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, leads Qu’s growing clinical trial program.

We have completed three Health Canada-approved clinical trials in Crohn’s disease, ulcerative colitis and recurrent lung cancer, successfully establishing proof-of-concept in inflammatory bowel disease (IBD) and cancer, and supporting continued development of QBECO SSI in IBD and QBKPN SSI in lung disease.

• For a summary of the results in Crohn’s disease, click here.
• For a summary of the results in ulcerative colitis, click here.
• For a summary of the results in lung cancer, click here.

To learn more about QBECO SSI for the treatment of IBD, visit www.quibd.com. To sign up for updates regarding our clinical trial programs in Crohn’s disease or ulcerative colitis, please visit here.